## FDG-PET/CT scanning for the detection of pelvic lymph node metastasis in penile carcinoma

Sarah R. Ottenhof<sup>1</sup>, R.S. Djajadiningrat<sup>1</sup>, M. Versleijen<sup>2</sup>, M. Donswijk<sup>2</sup>, NM Graafland<sup>1</sup>, Erik Vegt<sup>2</sup>, Simon Horenblas<sup>1</sup>

From the departments Urology (1) and Nuclear medicine (2) of the Netherlands Cancer Institute

## Introduction

For staging pelvic lymph nodes, CT and MRI have insufficient sensitivity of 20-50%<sup>1,2</sup>. In this retrospective cohort we describe the diagnostic accuracy of FDG-PET/CT for the staging of pelvic lymph nodes in patients with proven inguinal metastases.

**Aim**: To describe the diagnostic accuracy of FDG-PET/CT for staging pelvic lymph nodes in patients with proven inguinal metastases.


## Methods


Blinded revision of all PET/CT scans of patients with:


- bilateral or immobile inguinal metastases (cN2-cN3)
- positive fine-needle aspiration cytology (FNAC)
- positive imaging of regional lymph nodes.

Two methods of scoring on 4-point scale (see below): clinical assessment and semi-quantitative (activity compared to blood pool and liver). Reference: pelvic lymph node dissection (PLND) / positive imaging / follow-up > one year

| Score | Clinical                      | Semi-quantitative    |  |
|-------|-------------------------------|----------------------|--|
| 0     | not at all suspect            | normal               |  |
| 1     | reactive LN, ddx metastasis   | ≤ blood pool         |  |
| 2     | metastasis, ddx reactive LN   | > blood pool ≤ liver |  |
| 3     | highly suspect for metastasis | > liver              |  |







| 100 scans / 200 pelvic sides               | → 6 scans unavailable        |
|--|------------------------------|
|  | No reference:                |
| 91 scans / 169 pelvic sides                | 3 bilateral<br>13 unilateral |
| References: 63 PLND, 106 imaging/follow-up |                              |

| Test performances with 95% Confidence Intervals |                   |                   |                   |                   |  |  |  |  |
|---|-------------------|-------------------|-------------------|-------------------|--|--|--|--|
|   | Per pelvis        |                   | Per patient       |                   |  |  |  |  |
| %   | Clinical          | Semi-quant        | Clinical          | Semi-quant        |  |  |  |  |
| Sensitivity                                     | <b>89</b> [76-96] | <b>89</b> [76-96] | <b>85</b> [71-94] | <b>85</b> [71-94] |  |  |  |  |
| Specificity                                     | 76 [67-83]        | 69 [60-77]        | 62 [47-75]        | 54 [39-68]        |  |  |  |  |
| PPV   | <b>57</b> [49-65] | 51 [44-58]        | 64 [55-72]        | 59 [51-67]        |  |  |  |  |
| NPV   | 95 [89-98]        | 95 [88-98]        | 84 [71-92]        | 82 [68-91]        |  |  |  |  |

PPV, positive predictive value; NPV, negative predictive value

Further information: s.ottenhof@nki.nl

|                    | Clinical scoring      |                       | Semi-quantitative scoring |                       |
|--------------------|-----------------------|-----------------------|---------------------------|-----------------------|
|                    | Reference<br>positive | Reference<br>negative | Reference<br>positive     | Reference<br>negative |
| PET positive (2/3) | 40                    | 30                    | 40                        | 38                    |
| PET negative (0/1) | 5                     | 94                    | 5                         | 86                    |

## Conclusions

FDG-PET/CT showed **good test performance** for staging pelvic lymph nodes of penile carcinoma patients with inguinal metastasis. PET/CT is the **best available imaging modality** and can be a **useful tool** in the decision to perform a pelvic lymph node dissection.